302 related articles for article (PubMed ID: 27304841)
1. Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study.
Wongprikorn A; Sukasem C; Puangpetch A; Numthavej P; Thakkinstian A; Kiertiburanakul S
PLoS One; 2016; 11(6):e0157531. PubMed ID: 27304841
[TBL] [Abstract][Full Text] [Related]
2. Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study.
Srichatrapimuk S; Wongsa A; Sungkanuparph S; Kiertiburanakul S; Tassaneetrithep B; Phuphuakrat A
AIDS Res Ther; 2023 Feb; 20(1):13. PubMed ID: 36849967
[TBL] [Abstract][Full Text] [Related]
3. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.
Jao J; Yu W; Patel K; Miller TL; Karalius B; Geffner ME; DiMeglio LA; Mirza A; Chen JS; Silio M; McFarland EJ; Van Dyke RB; Jacobson D;
HIV Med; 2018 Mar; 19(3):175-183. PubMed ID: 29159965
[TBL] [Abstract][Full Text] [Related]
4. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial.
Ihm SH; Chung WB; Lee JM; Hwang BH; Yoo KD; Her SH; Song WH; Chae IH; Park TH; Kim JH; Jeon DW; Cho BR; Kang SH; Park SD; Lee JB; Woo JT; Lee BW; Han KA; Won KH; Kim HS; Yu JM; Chung CH; Kim HJ; Cho HC; Seung KB
Clin Ther; 2020 Oct; 42(10):2021-2035.e3. PubMed ID: 32891418
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial.
Sponseller CA; Morgan RE; Kryzhanovski VA; Campbell SE; Davidson MH
Clin Ther; 2014 Aug; 36(8):1211-22. PubMed ID: 24998014
[TBL] [Abstract][Full Text] [Related]
7. Greater remnant lipoprotein cholesterol reduction with pitavastatin compared with pravastatin in HIV-infected patients.
Joshi PH; Miller PE; Martin SS; Jones SR; Massaro JM; D'Agostino RB; Kulkarni KR; Sponseller C; Toth PP
AIDS; 2017 Apr; 31(7):965-971. PubMed ID: 28121706
[TBL] [Abstract][Full Text] [Related]
8. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
9. Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia.
Miller PE; Martin SS; Joshi PH; Jones SR; Massaro JM; D'Agostino RB; Sponseller CA; Toth PP
Clin Ther; 2016 Mar; 38(3):603-9. PubMed ID: 26922296
[TBL] [Abstract][Full Text] [Related]
10. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.
Casado JL; de Los Santos I; Del Palacio M; García-Fraile L; Pérez-Elías MJ; Sanz J; Moreno S
HIV Clin Trials; 2013; 14(1):1-9. PubMed ID: 23372109
[TBL] [Abstract][Full Text] [Related]
11. Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials.
Carey D; Amin J; Boyd M; Petoumenos K; Emery S
J Antimicrob Chemother; 2010 Sep; 65(9):1878-88. PubMed ID: 20554568
[TBL] [Abstract][Full Text] [Related]
12. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir.
Busti AJ; Bedimo R; Margolis DM; Hardin DS
J Investig Med; 2008 Feb; 56(2):539-44. PubMed ID: 18317438
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial.
Eriksson M; Budinski D; Hounslow N
Adv Ther; 2011 Sep; 28(9):811-23. PubMed ID: 21874538
[TBL] [Abstract][Full Text] [Related]
14. Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy.
Murphy RL; Berzins B; Zala C; Fichtenbaum C; Dube MP; Guaraldi G; Torriani F; Belsey E; Mitchell C; Stein JH;
AIDS; 2010 Mar; 24(6):885-90. PubMed ID: 19952712
[TBL] [Abstract][Full Text] [Related]
15. The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial.
Santos JR; Saumoy M; Curran A; Bravo I; Llibre JM; Navarro J; Estany C; Podzamczer D; Ribera E; Negredo E; Clotet B; Paredes R;
Clin Infect Dis; 2015 Aug; 61(3):403-8. PubMed ID: 25870325
[TBL] [Abstract][Full Text] [Related]
16. Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.
d'Ettorre G; Ceccarelli G; Zaccarelli M; Ascoli-Bartoli T; Bianchi L; Bellelli V; De Girolamo G; Serafino S; Giustini N; Mastroianni CM; Vullo V
Int J STD AIDS; 2016 Jul; 27(8):638-43. PubMed ID: 26068963
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
18. Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial.
Lu MT; Ribaudo H; Foldyna B; Zanni MV; Mayrhofer T; Karady J; Taron J; Fitch KV; McCallum S; Burdo TH; Paradis K; Hedgire SS; Meyersohn NM; DeFilippi C; Malvestutto CD; Sturniolo A; Diggs M; Siminski S; Bloomfield GS; Alston-Smith B; Desvigne-Nickens P; Overton ET; Currier JS; Aberg JA; Fichtenbaum CJ; Hoffmann U; Douglas PS; Grinspoon SK;
JAMA Cardiol; 2024 Apr; 9(4):323-334. PubMed ID: 38381407
[TBL] [Abstract][Full Text] [Related]
19. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
Gumprecht J; Gosho M; Budinski D; Hounslow N
Diabetes Obes Metab; 2011 Nov; 13(11):1047-55. PubMed ID: 21812889
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Pitavastatin in Japanese Male Children with Familial Hypercholesterolemia.
Harada-Shiba M; Arisaka O; Ohtake A; Okada T; Suganami H;
J Atheroscler Thromb; 2016; 23(1):48-55. PubMed ID: 25891210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
